Drug Discovery Informatics Market Report 2026

The drug discovery informatics market size has grown rapidly in recent years. It will grow from $4.06 billion in 2025 to $4.63 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing pharmaceutical r&d complexity, expansion of clinical trial data volumes, adoption of computational chemistry tools, growth in bioinformatics applications, rising demand for faster drug development cycles.

The drug discovery informatics market size is expected to see rapid growth in the next few years. It will grow to $7.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing investments in ai-enabled drug discovery, rising adoption of precision medicine approaches, expansion of collaborative research platforms, growing focus on predictive modeling accuracy, increasing integration of informatics with laboratory systems. Major trends in the forecast period include increasing use of ai-driven drug discovery platforms, rising adoption of cloud-based informatics solutions, growing integration of big data analytics in r&d, expansion of virtual screening and modeling tools, enhanced focus on data integration and management.

The increasing prevalence of various chronic diseases is expected to drive the growth of the drug discovery informatics market in the coming years. Chronic illnesses are generally defined as disorders that persist for a year or longer, require ongoing medical treatment, and may interfere with daily activities. Drug discovery informatics systems support the advancement of chronic disease care by enabling researchers to investigate complex and transient molecular changes that underlie disease progression and drug response, producing multi-dimensional models of the entire hierarchical system in healthy, diseased, and treated states. For example, in May 2024, the British Diabetic Association (Diabetes UK), a UK-based patient, healthcare professional, and research charity, reported that approximately 4.4 million people in the UK were living with a diabetes diagnosis as of 2022-23, with around 8% having type 1 diabetes and about 90% having type 2 diabetes. Hence, the rising prevalence of various chronic diseases is fueling the growth of the drug discovery informatics market.

Leading companies within the drug discovery informatics market are directing their efforts toward innovative offerings, such as AI-powered solutions in life sciences, to drive market revenues. AI-driven solutions in life sciences are instrumental in advancing precision medicine and drug discovery, potentially revolutionizing the creation of new therapies and personalized treatment plans. These advancements aim to enhance the speed, accuracy, and efficiency of research and development processes within the life sciences industry. For instance, in May 2023, Google Cloud Platform, a US-based technology company, introduced AI-powered life sciences solutions such as the Target and Lead Identification Suite and the Multiomics Suite. These solutions aim to transform life sciences enterprises by expediting drug research and hastening the introduction of novel treatments. Utilizing high-performance computing, generative AI, and sophisticated computational tools, these methods predict protein structures, delineate the function of amino acids, and analyze genetic data. The Multiomics Suite contributes to precision medicine tools, while the Target and Lead Identification Suite aids in more effective in silico drug design.

In May 2023, Recursion Pharmaceuticals, a US-based clinical-stage biotechnology company, acquired Cyclica Inc. for $40 million. Through this acquisition, Recursion strengthened its technology-driven drug discovery capabilities by combining Cyclica’s digital chemistry expertise with its own biological exploration strengths. Cyclica Inc., based in Canada, specializes in drug discovery informatics.

Major companies operating in the drug discovery informatics market are Accenture Plc.; Certara Inc.; Charles River Laboratories Inc.; Infosys Ltd.; Collaborative Drug Discovery Inc.; Eurofins DiscoverX Products Inc.; Jubilant Biosys Ltd.; Selvita S.A.; PerkinElmer Inc.; International Business Machines Corporation; Boehringer Ingelheim International GmbH; Oracle Corporation; Thermo Fisher Scientific Inc.; Albany Molecular Research Inc.; ChemAxon Ltd.; Amazon Web Services Inc.; Schrödinger LLC.; Core Informatics LLC; Informatics Matters Ltd.; Tata Consultancy Services Limited; Novo Informatics Pvt. Ltd.; IO Informatics Inc.; GVK Biosciences Private Limited; Dassault Systèmes SE; Recursion Pharmaceuticals Inc.; Cyclica Inc.; Valence Discovery Inc.; Valo Health Inc.; Cognizant Technology Solutions Corporation; Wipro Limited; Mindtree Limited; Persistent Systems Limited; Mphasis Limited.

North America was the largest region in the drug discover informatics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug discovery informatics market during the forecast period. The regions covered in the drug discovery informatics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery informatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the drug discovery informatics market by increasing costs of imported high-performance computing hardware, data storage systems, advanced servers, and specialized software infrastructure. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported computing equipment, while Asia-Pacific faces cost pressure on informatics infrastructure expansion. These tariffs are raising operational costs and delaying system upgrades. However, they are also encouraging cloud adoption, regional data center investments, and software-focused innovation models.

The drug discovery informatics market research report is one of a series of new reports that provides drug discovery informatics market statistics, including drug discovery informatics industry global market size, regional shares, competitors with a drug discovery informatics market share, detailed drug discovery informatics market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery informatics industry. This drug discovery informatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery informatics involves the development of systems designed to operate more efficiently with the vast volumes of clinical trial and treatment data. This field aims to facilitate the management of medical information, expediting the study and development of successful new treatments.

Key services in drug discovery informatics are categorized into in-house and outsourced solutions. In-house refers to computer programs, both in source and object code form, specifically tailored to the group's business needs and developed by the company itself rather than licensed from external sources. Various modalities, including cloud-based systems and in-campus applications, are employed for tasks such as data sequencing, molecular docking, identification and validation, as well as target data analysis. The end-users benefiting from these services encompass pharmaceutical companies, contract research organizations, and biotechnology companies.

The drug discovery informatics market consists of revenues earned by entities by providing literature databases, chemical databases, biological databases, predictive analytics, structures 2D and 3D, pharmacokinetic and pharmacodynamic data analysis, assay data analysis, genomics data analytics, and proteomics data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug discovery informatics market also includes sales of CI-based (continuous integration) design tools and pharmacophore modelling tools, which are used in providing drug discovery informatics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.